Shandong Weigao Group Medical Polymer Company Limited

SEHK:1066 Rapport sur les actions

Capitalisation boursière : HK$19.8b

Shandong Weigao Group Medical Polymer Gestion

Gestion contrôle des critères 3/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Rinan Cong

Directeur général

CN¥4.0m

Rémunération totale

Pourcentage du salaire du PDG42.1%
Durée du mandat du directeur généralno data
Propriété du PDG0.05%
Durée moyenne d'occupation des postes de direction2.4yrs
Durée moyenne du mandat des membres du conseil d'administration2.4yrs

Mises à jour récentes de la gestion

We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope

May 22
We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope

Recent updates

Be Wary Of Shandong Weigao Group Medical Polymer (HKG:1066) And Its Returns On Capital

Nov 04
Be Wary Of Shandong Weigao Group Medical Polymer (HKG:1066) And Its Returns On Capital

Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report

Sep 24
Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report

Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target

Aug 30
Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target

Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 27% Share Price Plunge Could Signal Some Risk

Jun 25
Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 27% Share Price Plunge Could Signal Some Risk

Here's What To Make Of Shandong Weigao Group Medical Polymer's (HKG:1066) Decelerating Rates Of Return

Jun 23
Here's What To Make Of Shandong Weigao Group Medical Polymer's (HKG:1066) Decelerating Rates Of Return

Shandong Weigao Group Medical Polymer's (HKG:1066) Shareholders Will Receive A Bigger Dividend Than Last Year

May 31
Shandong Weigao Group Medical Polymer's (HKG:1066) Shareholders Will Receive A Bigger Dividend Than Last Year

We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope

May 22
We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope

Earnings Not Telling The Story For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)

Apr 23
Earnings Not Telling The Story For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)

Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results

Mar 28
Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results

Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon

Jan 09
Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon

Returns On Capital Are Showing Encouraging Signs At Shandong Weigao Group Medical Polymer (HKG:1066)

Dec 22
Returns On Capital Are Showing Encouraging Signs At Shandong Weigao Group Medical Polymer (HKG:1066)

Are Investors Undervaluing Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) By 44%?

Nov 10
Are Investors Undervaluing Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) By 44%?

Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?

Oct 05
Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?

Return Trends At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Appealing

Aug 01
Return Trends At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Appealing

Is Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Trading At A 28% Discount?

Jul 19
Is Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Trading At A 28% Discount?

Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth

Jun 22
Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth

Is Shandong Weigao Group Medical Polymer (HKG:1066) Using Too Much Debt?

Jun 09
Is Shandong Weigao Group Medical Polymer (HKG:1066) Using Too Much Debt?

The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing

Apr 27
The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing

Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth

Mar 17
Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth

A Look At The Intrinsic Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)

Feb 27
A Look At The Intrinsic Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)

Returns On Capital At Shandong Weigao Group Medical Polymer (HKG:1066) Have Hit The Brakes

Jan 18
Returns On Capital At Shandong Weigao Group Medical Polymer (HKG:1066) Have Hit The Brakes

Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?

Dec 12
Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?

Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 21% Below Their Intrinsic Value Estimate

Nov 29
Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 21% Below Their Intrinsic Value Estimate

Here's Why We Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today

Nov 14
Here's Why We Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today

Shandong Weigao Group Medical Polymer (HKG:1066) Is Paying Out A Larger Dividend Than Last Year

Oct 03
Shandong Weigao Group Medical Polymer (HKG:1066) Is Paying Out A Larger Dividend Than Last Year

The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing

Sep 21
The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing

Shandong Weigao Group Medical Polymer (HKG:1066) Could Easily Take On More Debt

Sep 05
Shandong Weigao Group Medical Polymer (HKG:1066) Could Easily Take On More Debt

Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Intrinsic Value Is Potentially 27% Above Its Share Price

Aug 23
Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Intrinsic Value Is Potentially 27% Above Its Share Price

Here's Why Shandong Weigao Group Medical Polymer (HKG:1066) Has Caught The Eye Of Investors

Aug 08
Here's Why Shandong Weigao Group Medical Polymer (HKG:1066) Has Caught The Eye Of Investors

There's Been No Shortage Of Growth Recently For Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital

Jun 22
There's Been No Shortage Of Growth Recently For Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital

Shandong Weigao Group Medical Polymer (HKG:1066) Will Pay A Smaller Dividend Than Last Year

Jun 08
Shandong Weigao Group Medical Polymer (HKG:1066) Will Pay A Smaller Dividend Than Last Year

An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 27% Undervalued

May 16
An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 27% Undervalued

Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?

May 03
Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?

Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital Are Heading Higher

Mar 17
Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital Are Heading Higher

Is There An Opportunity With Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 42% Undervaluation?

Jan 28
Is There An Opportunity With Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 42% Undervaluation?

Does Shandong Weigao Group Medical Polymer (HKG:1066) Deserve A Spot On Your Watchlist?

Jan 13
Does Shandong Weigao Group Medical Polymer (HKG:1066) Deserve A Spot On Your Watchlist?

Returns Are Gaining Momentum At Shandong Weigao Group Medical Polymer (HKG:1066)

Dec 17
Returns Are Gaining Momentum At Shandong Weigao Group Medical Polymer (HKG:1066)

Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly

Dec 05
Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly

An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 32% Undervalued

Oct 18
An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 32% Undervalued

Do Shandong Weigao Group Medical Polymer's (HKG:1066) Earnings Warrant Your Attention?

Oct 06
Do Shandong Weigao Group Medical Polymer's (HKG:1066) Earnings Warrant Your Attention?

Analyse de la rémunération des PDG

Comment la rémunération de Rinan Cong a-t-elle évolué par rapport aux bénéfices de Shandong Weigao Group Medical Polymer?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

CN¥2b

Mar 31 2024n/an/a

CN¥2b

Dec 31 2023CN¥4mCN¥2m

CN¥2b

Sep 30 2023n/an/a

CN¥2b

Jun 30 2023n/an/a

CN¥2b

Mar 31 2023n/an/a

CN¥3b

Dec 31 2022CN¥5mCN¥950k

CN¥3b

Sep 30 2022n/an/a

CN¥3b

Jun 30 2022n/an/a

CN¥3b

Mar 31 2022n/an/a

CN¥2b

Dec 31 2021CN¥3mCN¥903k

CN¥2b

Rémunération vs marché: La rémunération totale de Rinan ($USD 550.82K ) est dans la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 515.49K ).

Rémunération et revenus: La rémunération de Rinan a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Rinan Cong (43 yo)

no data

Titularisation

CN¥3,990,000

Compensation

Mr. Rinan Cong served as Chief Executive Officer at Shandong Weigao Group Medical Polymer Company Limited since March 30, 2021 until 2024 and served as Executive Director since May 24, 2021 until 2024 and...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Jing Long
Executive Chairman of the Board & Compliance Officer5.9yrsCN¥8.27m0.14%
HK$ 28.1m
Rinan Cong
Chief Executive Officerno dataCN¥3.99m0.048%
HK$ 9.5m
Junqiang Lu
Executive Director2.4yrsCN¥1.32mpas de données
Xue Feng Wu
Chief Financial Officer7.8yrspas de donnéespas de données
Xia Yan
Non-Executive Directorless than a yearpas de donnéespas de données
Daoming Wang
Executive Directorless than a yearpas de données0.011%
HK$ 2.2m
Miu Ling Wong
Company Secretary18.5yrspas de donnéespas de données

2.4yrs

Durée moyenne de l'emploi

49yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 1066 est considérée comme expérimentée (ancienneté moyenne 2.4 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Jing Long
Executive Chairman of the Board & Compliance Officer5.9yrsCN¥8.27m0.14%
HK$ 28.1m
Junqiang Lu
Executive Director2.4yrsCN¥1.32mpas de données
Xia Yan
Non-Executive Directorless than a yearpas de donnéespas de données
Daoming Wang
Executive Directorless than a yearpas de données0.011%
HK$ 2.2m
Lin Chen
Non-Executive Director3.7yrspas de donnéespas de données
Hong Meng
Independent Non-Executive Director2.2yrsCN¥150.00kpas de données
Guohui Li
Independent Non-Executive Director2.4yrsCN¥207.00kpas de données
Zhengpeng Tang
Vice Chairman3.7yrspas de donnéespas de données
Meijun Gu
Chairman of the Supervisors4.3yrspas de donnéespas de données
Zhuangqiu Zhang
Employee Representative Supervisor2.6yrspas de donnéespas de données
Qiang Li
Independent Non-Executive Director1.9yrsCN¥150.00kpas de données
Heng Sun
Independent Non-Executive Directorless than a yearpas de donnéespas de données

2.4yrs

Durée moyenne de l'emploi

49yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la 1066 n'est pas considéré comme expérimenté ( 2.4 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.